{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:10:52Z","timestamp":1784718652479,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jhep.2019.06.002","type":"journal-article","created":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T23:00:00Z","timestamp":1560466800000},"page":"666-672","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs"],"prefix":"10.1016","volume":"71","author":[{"given":"Jordi","family":"Llaneras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Riveiro-Barciela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabela","family":"Lens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mois\u00e9s","family":"Diago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Cachero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Garc\u00eda-Samaniego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Conde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Arencibia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Arenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Gea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Torras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Luis Calleja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Antonio Carri\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Mar\u00eda Morillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Miguel","family":"Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrado","family":"Fern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Hern\u00e1ndez-Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Llerena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Turnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas M.","family":"Gonz\u00e1lez-Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Montoliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Figueruela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Badia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Fern\u00e1ndez-Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"I\u00f1arrairaegui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Pascasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Mari\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2019.06.002_b0005","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1146\/annurev-med-052915-015720","article-title":"Oral combination therapies for hepatitis C virus infection: successes, challenges, and unmet needs","volume":"68","author":"Naggie","year":"2017","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jhep.2019.06.002_b0010","doi-asserted-by":"crossref","unstructured":"EASL Recommendations on Treatment of Hepatitis C 2018. Journal of hepatology. 2018;69:461\u2013511.","DOI":"10.1016\/j.jhep.2018.03.026"},{"key":"10.1016\/j.jhep.2019.06.002_b0015","doi-asserted-by":"crossref","unstructured":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology (Baltimore, Md). 2015;62(3):932\u2013954.","DOI":"10.1002\/hep.27950"},{"key":"10.1016\/j.jhep.2019.06.002_b0020","doi-asserted-by":"crossref","unstructured":"Hepatitis C Guidance 2018 Update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;67(10):1477\u20131492.","DOI":"10.1093\/cid\/ciy585"},{"key":"10.1016\/j.jhep.2019.06.002_b0025","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.06.002_b0030","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jiph.2017.09.004","article-title":"Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: a systematic review and meta-analysis","volume":"11","author":"Ahmed","year":"2018","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.jhep.2019.06.002_b0035","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2018.11.011","article-title":"Real-life effectiveness and safety of Glecaprevir\/Pibrentasvir in 723 patients with chronic hepatitis C","volume":"70","author":"D'Ambrosio","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.06.002_b0040","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/apt.14527","article-title":"Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA","volume":"47","author":"Chhatwal","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2019.06.002_b0045","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3851\/IMP3202","article-title":"Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3\/4A protease inhibitor","volume":"23","author":"Lawitz","year":"2018","journal-title":"Antiviral Ther"},{"key":"10.1016\/j.jhep.2019.06.002_b0050","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1053\/j.gastro.2016.07.039","article-title":"Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with genotype 1 hepatitis C virus infection in an open-label, phase 2 trial","volume":"151","author":"Lawitz","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.06.002_b0055","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/hep.29130","article-title":"Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus","volume":"65","author":"Lawitz","year":"2017","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10.1016\/j.jhep.2019.06.002_b0060","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourliere","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.06.002_b0065","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S2468-1253(18)30118-3","article-title":"Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1","volume":"3","author":"Bourliere","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.06.002_b0070","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.06.002_b0075","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.06.002_b0080","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance-associated substitutions: state of the art summary","volume":"62","author":"Lontok","year":"2015","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10.1016\/j.jhep.2019.06.002_b0085","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40265-018-0864-z","article-title":"Ledipasvir\/sofosbuvir: a review in chronic hepatitis C","volume":"78","author":"Scott","year":"2018","journal-title":"Drugs."},{"key":"10.1016\/j.jhep.2019.06.002_b0090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jhep.2016.08.021","article-title":"Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients","volume":"66","author":"Pol","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.06.002_b0095","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s40265-017-0739-8","article-title":"Elbasvir\/grazoprevir: a review in chronic HCV genotypes 1 and 4","volume":"77","author":"Al-Salama","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.jhep.2019.06.002_b0100","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s40265-016-0612-1","article-title":"Ombitasvir\/paritaprevir\/ritonavir: a review in chronic HCV genotype 4 infection","volume":"76","author":"Keating","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jhep.2019.06.002_b0105","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40265-015-0412-z","article-title":"Ombitasvir\/paritaprevir\/ritonavir plus dasabuvir: a review in chronic HCV genotype 1 infection","volume":"75","author":"Deeks","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.jhep.2019.06.002_b0110","doi-asserted-by":"crossref","unstructured":"EASL recommendations on treatment of hepatitis C 2014. Journal of hepatology. 2014;61(2):373\u2013395.","DOI":"10.1016\/j.jhep.2014.05.001"},{"key":"10.1016\/j.jhep.2019.06.002_b0115","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0168-8278(18)30732-3","article-title":"Sofosbuvir+Glecaprevir\/Pibrentasvir in patients with difficult to treat HCV infection. Final results of the French compassionate use","volume":"68","author":"De Ledinghen","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.06.002_b0120","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jhep.2019.01.031","article-title":"Retreatment of patients who failed glecaprevir\/pibrentasvir treatment for hepatitis C virus infection","volume":"70","author":"Wyles","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.06.002_b0125","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1053\/j.gastro.2017.12.015","article-title":"Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1\u20137 and escape variants","volume":"154","author":"Gottwein","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.06.002_b0130","first-page":"142A","article-title":"Real-world effectiveness of sofosbuvir\/velpatasvir\/voxilaprevir in 573 treatment-experienced patients with hepatitis C genotypes 1 through 4","volume":"68","author":"Belperio","year":"2018","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10.1016\/j.jhep.2019.06.002_b0135","first-page":"374A","article-title":"Sofosbuvir + velpatasvir + voxilaprevir in Daa failure patients with cirrhosis. Final results of the french compassionate use program","volume":"68","author":"Hezode","year":"2018","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10.1016\/j.jhep.2019.06.002_b0140","first-page":"419A","article-title":"Sofosbuvir\/velpatasvir\/voxilaprevir (SOF\/VEL\/VOX) in care of chronic hepatitis C patients; clinical practice experience from the trio network","volume":"68","author":"Bacon","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.06.002_b0145","first-page":"401A","article-title":"Sarrazin C and german hepatitis registry retreatment with voxilaprevir\/velpatasvir\/sofosbuvir in patients with chronic hepatitis C virus infection and prior DAA failure \u2013 results from the german hepatitis C-registry (DHC-R)","volume":"68","author":"Vermehren","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.06.002_b0150","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jhep.2018.07.002","article-title":"Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection","volume":"69","author":"Vermehren","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.06.002_b0155","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jhep.2018.07.023","article-title":"No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients","volume":"69","author":"Sarrazin","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.06.002_b0160","first-page":"361A","article-title":"Sofosbuvir\/velpatasvir\/voxilaprevir (SOF\/VEL\/VOX) for prior treatment failures with glecaprevir\/pibrentasvir (G\/P) in chronic hepatitis C infection","volume":"68","author":"Pearlman","year":"2018","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10.1016\/j.jhep.2019.06.002_b0165","first-page":"346A","article-title":"Retreatment with SOF\/VEL\/VOX in treatment-experience patients with and without HIV: the resolve study","volume":"68","author":"Covert","year":"2018","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819303459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819303459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:35:54Z","timestamp":1759174554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827819303459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0168827819303459"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2019.06.002","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2019.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}